Compounded Semaglutide With B12, Glycine or L-Carnitine: What the Add-Ins Actually Do

The short answer

There is little patient-level evidence that adding vitamin B12, glycine or L-carnitine to compounded semaglutide improves results or reduces side effects. A February 2026 editorial in the Annals of Pharmacotherapy reviewed compounded semaglutide and tirzepatide products and concluded it found "little justification for adding nutrients." The add-ins became common partly for marketing and partly because combinations were seen as a way to differentiate a compounded product from the approved drug, a strategy FDA's April 2026 policy statement narrowed considerably.

None of this means a combination product is dangerous by default. It means the add-in is not a reason to choose one product over another, and you should know why it is there.

What the 2026 review found

The editorial, "Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown" (Belcourt, Sapowadia and White, Annals of Pharmacotherapy, published online February 14, 2026), catalogued products on the market:

• 33 unique semaglutide and/or tirzepatide products, about two-thirds containing semaglutide.
• 48% were combinations with cyanocobalamin (B12), glycine, niacinamide, docusate or ondansetron.
• Of the 17 single-ingredient products, 82% were sublingual and 18% were orally disintegrating tablets.

The authors' conclusion: "We found little justification for adding nutrients or docusate sodium." They noted "there is a rationale for adding ondansetron, but evidence for subcutaneous administration is lacking." For glycine they described a plausible rationale but no patient data with these drugs.

Note that this is an editorial cataloguing products and reviewing the rationale, not a clinical trial. It tells you what is being sold and what evidence exists, not how any individual product performs. Study type matters: a catalog of products and a randomized trial answer very different questions.

Add-in by add-in

Vitamin B12 (cyanocobalamin)

The pitch: energy, reduced fatigue or nausea, or "supporting metabolism." What's real: B12 is an essential vitamin, and deficiency is a genuine medical problem that clinicians test for and treat. What's missing: evidence that adding B12 to a semaglutide injection improves weight loss or tolerability in people who are not deficient. If you suspect deficiency, that is a blood test and a separate conversation with a clinician.

Glycine

The pitch: glycine is an amino acid sometimes described as supporting metabolic health or stabilizing the formulation. What's real: the editorial authors describe a plausible rationale. What's missing: patient data for glycine combined with semaglutide or tirzepatide. The approved drugs were tested without it.

L-carnitine

The pitch: "fat burning." What's real: L-carnitine is involved in transporting fatty acids into mitochondria, which is where the marketing story comes from. What's missing: the 2026 editorial did not include L-carnitine combinations, and we did not find published patient data on semaglutide combined with L-carnitine. A biochemical role is not evidence that adding it to an injection changes outcomes.

The others: niacinamide, docusate, ondansetron

The editorial also found niacinamide (a form of vitamin B3), docusate (a stool softener) and ondansetron (an anti-nausea drug) in combinations. Ondansetron is the one the authors said has a rationale, since nausea is a known GLP-1 side effect, but they noted evidence for giving it by subcutaneous injection is lacking. It is also a prescription drug with its own interactions, which is worth knowing if it is in your vial. See our overview of peptide and prescription drug interactions.

Why pharmacies add them: the "essentially a copy" rule

Federal compounding law restricts pharmacies from regularly compounding drugs that are "essentially copies" of commercially available approved drugs. With semaglutide and tirzepatide no longer on FDA's drug shortage list, the room for compounding plain copies narrowed sharply; our explainers on the 503B GLP-1 exclusion and compounded vs brand semaglutide cover that history.

Adding an ingredient was one way some compounders argued a product was no longer a copy. FDA's April 1, 2026 statement, as summarized by Foley & Lardner, addressed this directly:

• A compounded GLP-1 is considered essentially a copy if it has the same active ingredient as the approved product in the same, similar or easily substitutable strength, and the approved product can be used by the same route.
• Semaglutide combined with cyanocobalamin is still treated as essentially a copy when the route is the same and the strengths are within 10% of the commercially available products' strengths.
• A prescriber can rebut that by determining and documenting a change that produces a significant difference for an identified individual patient. FDA has not said what documentation is required.
• For 503A pharmacies, FDA said it does not intend to act against compounding such a product if the pharmacy fills four or fewer prescriptions for it in a calendar month.
• The article notes that semaglutide and tirzepatide are not on the 503B bulks list or FDA's drug shortage list, and that the statement is policy, not law.

Separately, FDA says salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate, should not be used in compounding, and that it is not aware of any lawful basis for their use.

Safety context

FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, reports that as of May 31, 2026 it had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and notes these are likely underreported. Some reports involved dosing errors from patients measuring and self-administering incorrect doses. Our side effects and safety guide covers the broader picture.

If you already use a combination product

None of the above is a reason to stop or switch a prescription on your own. A few practical steps instead:

• Read the label and ask for the full formulation. Know every ingredient and its form, so you can tell other clinicians exactly what you take.
• Raise the evidence question with your prescriber. Ask why the add-in was chosen for you and whether a plain formulation would serve you equally well.
• Watch for changes when a formulation changes. If a pharmacy switches what it adds, or switches from injection to a sublingual or oral form, ask what changed and why. The 2026 editorial found many compounded products use routes and combinations that were never tested in trials.
• Report problems. If you have a side effect, tell your prescriber and the pharmacy, and consider reporting to FDA's MedWatch program.

B12 deserves one more note: if you have a condition or take a medicine that affects B12 levels, the place to address that is a blood test and a decision by your clinician, not a default add-in.

Questions to ask about a combination product

Dosing for prescription peptides is set by the prescribing clinician. PeptideOnline does not publish dosing, injection or reconstitution protocols. See our medical disclaimer.